



Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

May 4, 2026

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for *Jemperli* with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 1:30pm ET.

To register for the conference, please visit <https://hcwevents.com/royalty-company-conference>.

About Anaptys

Anaptys manages the financial collaborations for *Jemperli* with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www.AnaptysBio.com or follow us on [LinkedIn](#).

Contact:

Anaptys Investor Relations
investors@anaptysbio.com



Source: AnaptysBio, Inc.